Get started
Author

Thierry Chatellier

Observed names: Chatellier, T., T. Chatellier, Thierry CHATELLIER
ORCID: 0000-0001-8095-0118
Observed ORCID: 0000-0001-8095-0118
OpenAlex ID: A5065476891
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
2021 · Joël Guigay, Anne Aupérin, et al. · The Lancet Oncology · 240
Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial
2018 · Yungan Tao, Anne Auperin, et al. · Journal of Clinical Oncology · 77
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
2023 · E. Pons-Tostivint, P. Hulo, et al. · Cancer Immunology Immunotherapy · 27
PDF
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers
2024 · Marco Tagliamento, Marie Morfouace, et al. · npj Precision Oncology · 19
PDF
Multicenter Randomized Double-Blind, Placebo-Controlled Trial GORTEC (Groupe Oncologie Radiotherapie Tete et Cou) 2009-01 Evaluating the Effect of the Regenerating Agent on Radiodermatitis of Head and Neck Cancer Patients
2017 · Yungan Tao, Anne Auperin, et al. · International Journal of Radiation Oncology*Biology*Physics · 16
Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial
2024 · Joël Guigay, Hervé Le Caer, et al. · The Lancet Healthy Longevity · 13
PDF
Cetuximab-radiotherapy versus cetuximab-radiotherapy plus concurrent chemotherapy in patients with N0-N2a squamous cell carcinoma of the head and neck (SCCHN): Results of the GORTEC 2007-01 phase III randomized trial.
2016 · Jean Bourhis, xu Shan Sun, et al. · Journal of Clinical Oncology · 13
Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients
2019 · Eric Voog, Boris Campillo‐Gimenez, et al. · International Journal of Cancer · 10
PDF
914MO Standard versus fractionated high dose cisplatin concomitant with radiotherapy in locally advanced head & neck squamous cell cancer (LA-HNSCC): Results of the GORTEC 2015-02 CisFRad randomized trial
2020 · C. Borel, X. Sun, et al. · Annals of Oncology · 8
Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial
2024 · Christian Borel, Xu-Shan Sun, et al. · Radiotherapy and Oncology · 6
PDF
Masitinib plus FOLFIRI for second line treatment of metastatic colorectal cancer: An open label phase Ib/II trial.
2015 · Julien Taieb, Christophe Borg, et al. · Journal of Clinical Oncology · 5
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
2023 · E. Pons-Tostivint, P. Hulo, et al. · Cancer Immunology Immunotherapy · 3
PDF
Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics
2016 · C. Lepage, J.-M. Phelip, et al. · Annals of Oncology · 3
PDF
Long-term real-world outcomes of nivolumab+ipilimumab treatment of unresectable pleural mesothelioma: update of Meso-Immune GFPC 04-2021 study
2026 · Jean-Baptiste Assié, Laurent Greillier, et al. · Lung Cancer · 1
Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort
2022 · Sylvain Manfredi, Marie Dior, et al. · Cancer Medicine · 1
PDF
Clinical efficiency of remote symptom monitoring using electronic patient-reported outcome (ePRO) in lung cancer: Results of the prospective, multicenter REAL-MOOV-LUNG trial.
2026 · Nicolas Girard, Sylvain Dureau, et al. · Journal of Clinical Oncology
PDF
Qualité de vie (QdV) au diagnostic pour les patients porteurs d’un CBNPC de stade III non résécable : résultats de l’étude prospective nationale française OBSTINATE (GFPC 06-2019)
2025 · C. Ricordel, C. Christos, et al. · Revue des Maladies Respiratoires Actualités
1249P Health-related quality of life (HRQoL) at diagnosis for unresectable stage III NSCLC: Results from the French nationwide prospective study OBSTINATE (GFPC 06-2019)
2024 · C. Ricordel, A. Anota, et al. · Annals of Oncology
PDF
66P Incidence and impact on survival of venous thromboembolic events in patients with advanced non-small cell lung cancer receiving pembrolizumab as first-line of treatment
2022 · P. Hulo, H. Senellart, et al. · Annals of Oncology
PDF
Nivolumab in non-small cell lung cancer: French evaluation of use, current practices and medicoeconomic approach, Annals of Oncology, Volume 29, viii534, 2018
2018 · Grude, Françoise, Corre, R., et al. · HAL
PDF
Nivolumab in non-small cell lung cancer: French evaluation of use, current practices and medico-economic approach
2018 · F. Grude, R. Corre, et al. · Annals of Oncology
EGFR mutation detection in plasma of lung tumor patients to predict success in treatment with tyrosine kinase inhibitors in a routine clinical setting.
2016 · Marc G. Denis, Sandrine Hiret, et al. · Journal of Clinical Oncology
Works count: 22
Citation count: 442
H-index: 8
I10-index: 8
Year
Topic
Type